In patients with AA amyloidosis, gastrointestinal involvement can manifest as chronic diarrhea or protein-wasting enteropathy. This scenario requires a targeted clinical approach with the goal of controlling these specific manifestations.
Patients with AA amyloidosis who present with diarrhea or protein-wasting enteropathy represent a distinct subgroup in whom gastrointestinal symptom control is the primary therapeutic objective. The treatment goal is amelioration of diarrhea or protein-wasting enteropathy.
Management in this setting may involve antibiotic-based strategies targeting the gastrointestinal tract, among other therapeutic options detailed in the full protocol.
The complete algorithm — all options, applicable conditions, and decision criteria — is available in the structured protocol below.
DOI: 10.2147/CLEP.S39981
Furthermore, diarrhea or protein-wasting enteropathy may be ameliorated by the use of antibiotics to diminish bacterial overgrowth, prednisone pulses, or the combination of prednisolone and octreotide.
View source ↗